In a four-country survey, nail detachment was reported by 39 percent of GLP-1 users and 9 percent of people who never took them

What the research found

Conference report (cross-sectional survey, not a journal trial). ScienceDaily on 12 Oct 2026 summarized a briefing presented at the European Academy of Dermatology and Venereology Congress 2026, led by Charles Taïeb and Bruno Halioua, with institutional support from Ducray Laboratories (Pierre Fabre). The page's journal-reference line points at a different JAMA Network Open paper about prescribing trends. This write-up does not use that DOI. Researchers compared 575 people using GLP-1 medicines, with named examples including semaglutide products such as Ozempic and Wegovy and tirzepatide products such as Mounjaro, with 1,329 people who had type 2 diabetes and/or obesity and had never used them. Participants were in France, the United States, Brazil, and Mexico. Nail detachment was reported by 39 percent of users and 9 percent of never-users. Any nail disorder: 66 percent versus 53 percent. Nail discoloration: 46 percent versus 17 percent. About half of users said nail problems had started before the regimen. After accounting for existing skin conditions and nutritional gaps, detachment and discoloration were still about two to three times as common. In the same people, unusual hair loss was 50 percent versus 34 percent, and hair loss that began after the regimen started was 26 percent versus 12 percent. Scalp redness was about three times as frequent in users. Weight loss did not fully explain the gaps. The surveys are self-report, not exams, and they cannot prove the medicines caused the changes. Do not stop a prescribed GLP-1 medicine on your own. Not medical advice. Not a substitute for a prescribed medicine. Off-label use is clinician-only.

Evidence level: Animal study. Results in animals or cells often don't carry over to people.

Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline.

Read the original at EADV Congress 2026 briefing via ScienceDaily